Rethinking Phase I: Five strategies for faster proof of concept
For emerging biotechs, the goal isn't just speed — it's reaching strategic milestones with the data needed to make go/no-go decisions. To navigate the complexities of early development, companies must prioritize capital efficiency and clinical precision.
In the webinar, our Clinical Trialblazers expert panel shares strategies for streamlining Phase I programs and identifying your most promising assets sooner and maximizing the value of your development program.
What you'll get from this webinar:
- Understand which innovative trial designs actually work — and which are overhyped
- Learn how to deliver defensible go/no-go decisions in weeks through modernized data operations
- Discover how to navigate global regulatory complexity early to de-risk your development path
- Explore when and how to leverage AI and advanced modeling to accelerate timelines
- Identify the operational bottlenecks that drain capital and delay critical decisions
Related Insights
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
Related Insights
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026